
Search
Selected Filters
Filter Results
Displaying 1–10 of 242 research results
-
May 23, 2023
Summary of the Eighth Annual Retinal Cell & Gene Therapy Innovation Summit 2023
The Retinal Cell and Gene Therapy Innovation Summit has emerged as one of the most essential events for researchers and companies developing treatments and cures for retinal degenerative diseases. In its eighth year, the Innovation Summit featured 30 presentations from retina experts from around the world with more than 300 people in attendance.
-
May 2, 2023
Atsena Receives FDA Authorization to Launch a Gene Therapy Clinical Trial for XLRS
Known as The Lighthouse Study, the Phase ½ trial is expected to begin in mid-2023
-
May 1, 2023
Eric Pierce Receives Proctor Medal for Outstanding Achievements in Retinal Research
During his Proctor Award Lecture, Dr. Pierce reviewed encouraging clinical trial results for Editas’ CRISPR/Cas9 treatment for people with LCA10
-
Apr 28, 2023
Dr. Tucker is leading the development of GMP facilities for manufacturing clinical grade retinal therapies
-
Apr 21, 2023
Clinical trial participants with advanced vision loss from RP were able to identify fruits and vegetables
-
Mar 30, 2023
Most participants with advanced retinitis pigmentosa (RP) in the trial had improved navigation and/or object discrimination in reduced lighting conditions
-
Feb 18, 2023
Geographic atrophy (GA) is the advanced form of dry age-related macular degeneration (AMD) which causes blindness in one million people in the United States and 5 million worldwide.
This is the first time that a treatment has been approved for this leading cause of blindness.
-
Jan 3, 2023
Opus Genetics Acquires Rights to Gene Therapies for BEST1 and RP (RHO)
The company plans to seek clinical trial authorization for the BEST1 gene therapy during the second half of 2023
-
Dec 2, 2022
SparingVision Receives Authorization to Launch US Clinical Trial for its Cone-Preserving Treatment
The emerging therapy is designed to work independent of the mutated gene causing retinitis pigmentosa
-
Dec 2, 2022
Opus Genetics to Launch Gene Therapy Clinical Trial for LCA5 Patients
The LCA5 gene therapy will be the first emerging Opus treatment to move into a human study